BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Teixeira MI, Lopes CM, Amaral MH, Costa PC. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur J Pharm Biopharm 2020;149:192-217. [PMID: 31982574 DOI: 10.1016/j.ejpb.2020.01.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Fressinaud C, Thomas O, Umerska AM, Saulnier P. Lipid Nanoparticles Vectorized with NFL-TBS.40-63 Peptide Target Oligodendrocytes and Promote Neurotrophin-3 Effects After Demyelination In Vitro. Neurochem Res 2020;45:2732-48. [PMID: 32910302 DOI: 10.1007/s11064-020-03122-y] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Fagionato Masiero J, Barbosa EJ, de Oliveira Macedo L, de Souza A, Nishitani Yukuyama M, Arantes GJ, Bou-chacra NA. Vegetable oils in pharmaceutical and cosmetic lipid-based nanocarriers preparations. Industrial Crops and Products 2021;170:113838. [DOI: 10.1016/j.indcrop.2021.113838] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
3 Teixeira MI, Lopes CM, Gonçalves H, Catita J, Silva AM, Rodrigues F, Amaral MH, Costa PC. Formulation, Characterization, and Cytotoxicity Evaluation of Lactoferrin Functionalized Lipid Nanoparticles for Riluzole Delivery to the Brain. Pharmaceutics 2022;14:185. [PMID: 35057079 DOI: 10.3390/pharmaceutics14010185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Tripathi S, Gupta U, Ujjwal RR, Yadav AK. Nano-lipidic formulation and therapeutic strategies for Alzheimer's disease via intranasal route. J Microencapsul 2021;38:572-93. [PMID: 34591731 DOI: 10.1080/02652048.2021.1986585] [Reference Citation Analysis]
5 Witika BA, Poka MS, Demana PH, Matafwali SK, Melamane S, Malungelo Khamanga SM, Makoni PA. Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date. Pharmaceutics 2022;14:836. [DOI: 10.3390/pharmaceutics14040836] [Reference Citation Analysis]
6 Hernando S, Herran E, Hernandez RM, Igartua M. Nanostructured Lipid Carriers Made of Ω-3 Polyunsaturated Fatty Acids: In Vitro Evaluation of Emerging Nanocarriers to Treat Neurodegenerative Diseases. Pharmaceutics 2020;12:E928. [PMID: 33003360 DOI: 10.3390/pharmaceutics12100928] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Binda A, Murano C, Rivolta I. Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer's Disease: A State-of-the-Art (2017-2020). Int J Nanomedicine 2020;15:6113-35. [PMID: 32884267 DOI: 10.2147/IJN.S231480] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
8 Fakhri S, Abdian S, Zarneshan SN, Moradi SZ, Farzaei MH, Abdollahi M. Nanoparticles in Combating Neuronal Dysregulated Signaling Pathways: Recent Approaches to the Nanoformulations of Phytochemicals and Synthetic Drugs Against Neurodegenerative Diseases. IJN 2022;Volume 17:299-331. [DOI: 10.2147/ijn.s347187] [Reference Citation Analysis]
9 Metaxakis A, Petratou D, Tavernarakis N. Molecular Interventions towards Multiple Sclerosis Treatment. Brain Sci 2020;10:E299. [PMID: 32429225 DOI: 10.3390/brainsci10050299] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Podbielska M, O'Keeffe J, Pokryszko-Dragan A. New Insights into Multiple Sclerosis Mechanisms: Lipids on the Track to Control Inflammation and Neurodegeneration. Int J Mol Sci 2021;22:7319. [PMID: 34298940 DOI: 10.3390/ijms22147319] [Reference Citation Analysis]
11 Jan Z, Mollazadeh S, Abnous K, Taghdisi SM, Danesh A, Ramezani M, Alibolandi M. Targeted Delivery Platforms for the Treatment of Multiple Sclerosis. Mol Pharm 2022. [PMID: 35501974 DOI: 10.1021/acs.molpharmaceut.1c00892] [Reference Citation Analysis]
12 Abbas M. Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer's Patients. Polymers (Basel) 2021;13:1051. [PMID: 33801619 DOI: 10.3390/polym13071051] [Reference Citation Analysis]
13 Teixeira MI, Amaral MH, Costa PC, Lopes CM, Lamprou DA. Recent Developments in Microfluidic Technologies for Central Nervous System Targeted Studies. Pharmaceutics 2020;12:E542. [PMID: 32545276 DOI: 10.3390/pharmaceutics12060542] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
14 Mozafari N, Ashrafi H, Azadi A. Targeted drug delivery systems to control neuroinflammation in central nervous system disorders. Journal of Drug Delivery Science and Technology 2021;66:102802. [DOI: 10.1016/j.jddst.2021.102802] [Reference Citation Analysis]
15 Gallego I, Villate-Beitia I, Saenz-Del-Burgo L, Puras G, Pedraz JL. Therapeutic Opportunities and Delivery Strategies for Brain Revascularization in Stroke, Neurodegeneration, and Aging. Pharmacol Rev 2022;74:439-61. [PMID: 35302047 DOI: 10.1124/pharmrev.121.000418] [Reference Citation Analysis]
16 Mousavi SM, Babazadeh M, Nemati M, Es’haghi M. Doxorubicin-loaded biodegradable chitosan–graphene nanosheets for drug delivery applications. Polym Bull . [DOI: 10.1007/s00289-021-03783-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Perrelli A, Fatehbasharzad P, Benedetti V, Ferraris C, Fontanella M, De Luca E, Moglianetti M, Battaglia L, Retta SF. Towards precision nanomedicine for cerebrovascular diseases with emphasis on Cerebral Cavernous Malformation (CCM). Expert Opin Drug Deliv 2021;18:849-76. [PMID: 33406376 DOI: 10.1080/17425247.2021.1873273] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Eshraghi M, Ahmadi M, Afshar S, Lorzadeh S, Adlimoghaddam A, Rezvani Jalal N, West R, Dastghaib S, Igder S, Torshizi SRN, Mahmoodzadeh A, Mokarram P, Madrakian T, Albensi BC, Łos MJ, Ghavami S, Pecic S. Enhancing autophagy in Alzheimer's disease through drug repositioning. Pharmacol Ther 2022;237:108171. [PMID: 35304223 DOI: 10.1016/j.pharmthera.2022.108171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wan J, Long Y, Liu S, Zhang Y, Xiang Y, Li D, Shi A, Shuang Y, Li Y, He Y, Li N, Guan Y. Geniposide-Loaded Liposomes for Brain Targeting: Development, Evaluation, and In Vivo Studies. AAPS PharmSciTech 2021;22:222. [PMID: 34409515 DOI: 10.1208/s12249-021-02093-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
20 Seo MW, Park TE. Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases. Biomed Eng Lett 2021;11:211-6. [PMID: 34350048 DOI: 10.1007/s13534-021-00198-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zhang Y, Yang H, Wei D, Zhang X, Wang J, Wu X, Chang J. Mitochondria‐targeted nanoparticles in treatment of neurodegenerative diseases. Exploration 2021;1:20210115. [DOI: 10.1002/exp.20210115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
22 Varshney M, Kumar B, Rana VS, Sethiya NK. An overview on therapeutic and medicinal potential of poly-hydroxy flavone viz. Heptamethoxyflavone, Kaempferitrin, Vitexin and Amentoflavone for management of Alzheimer's and Parkinson's diseases: a critical analysis on mechanistic insight. Crit Rev Food Sci Nutr 2021;:1-24. [PMID: 34590507 DOI: 10.1080/10408398.2021.1980761] [Reference Citation Analysis]
23 Riccardi C, Napolitano F, Montesarchio D, Sampaolo S, Melone MAB. Nanoparticle-Guided Brain Drug Delivery: Expanding the Therapeutic Approach to Neurodegenerative Diseases. Pharmaceutics 2021;13:1897. [PMID: 34834311 DOI: 10.3390/pharmaceutics13111897] [Reference Citation Analysis]
24 Nguyen TT, Nguyen TTD, Tran NM, Van Vo G. Lipid-Based Nanocarriers via Nose-to-Brain Pathway for Central Nervous System Disorders. Neurochem Res 2021. [PMID: 34800247 DOI: 10.1007/s11064-021-03488-7] [Reference Citation Analysis]